In Vitro Epiretinal Membrane Model and Antibody Permeability: Relationship With Anti-VEGF Resistance in Diabetic Macular Edema | Zendy

Rimba | Zendy; Hiroki Kaneko | Zendy; Ayana Suzumura | Zendy; Hideyuki Shimizu | Zendy; Keiko Kataoka | Zendy; Kei Takayama | Zendy; Kazuhisa Yamada | Zendy; Yasuhito Funahashi | Zendy; Seina Ito | Zendy; Norie obe | Zendy; Hiroko Terasaki | Zendy

Open Access

In Vitro Epiretinal Membrane Model and Antibody Permeability: Relationship With Anti-VEGF Resistance in Diabetic Macular Edema

Author(s) -

Rimba,

Hiroki Kaneko,

Ayana Suzumura,

Hideyuki Shimizu,

Keiko Kataoka,

Kei Takayama,

Kazuhisa Yamada,

Yasuhito Funahashi,

Seina Ito,

Norie obe,

Hiroko Terasaki

Publication year - 2019

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.19-26788

Subject(s) - ophthalmology , in vitro , epiretinal membrane , medicine , diabetic retinopathy , antibody , vascular permeability , macular edema , retinal , permeability (electromagnetism) , edema , visual acuity , chemistry , immunology , endocrinology , membrane , diabetes mellitus , biochemistry , vitrectomy

Diabetic macular edema (DME) is characterized by an accumulation of fluid in the macula due to diabetic retinopathy. Currently, anti-VEGF drugs are the standard treatment worldwide for DME. This study aimed to assess whether the existence of epiretinal membrane (ERM) affects anti-VEGF efficacy, due to reduced permeability of the antibody through the ERM.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research